Rigel Pharmaceuticals
Rigel Pharmaceuticals' revenue rose 64.2% to $294 million in fiscal 2025. Its operating margin was 42.6%, up from 13.5% a year earlier. The diluted share count rose 6.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Rigel Pharmaceuticals does
Rigel Pharmaceuticals develops and sells drugs for blood disorders and cancer. It has three FDA-approved products. TAVALISSE treats adults with chronic immune thrombocytopenia (ITP), a condition with low platelet counts, when an earlier treatment did not work well enough. REZLIDHIA treats adults with relapsed or refractory acute myeloid leukemia with a specific IDH1 mutation. GAVRETO, which Rigel began selling in June 2024, treats certain lung and thyroid cancers driven by a RET gene change.
Rigel earns money from net sales of these three medicines, mostly in the United States. TAVALISSE is also sold in Europe, the United Kingdom, Japan, Korea, Canada and Israel. It in-licensed REZLIDHIA from Forma Therapeutics, now part of Novo Nordisk, and bought the US rights to GAVRETO from Blueprint Medicines, now part of Sanofi. Rigel also receives payments from partners.
Its pipeline includes R289, a drug being tested in patients with lower-risk myelodysplastic syndrome, a group of bone marrow disorders. It is also testing olutasidenib with research partners in other diseases with IDH1 mutations. Eli Lilly leads a program for a third drug, an RIPK1 inhibitor.
Its biggest risks, as it describes them
- Its three approved products may sell less than it expects, or the markets may be smaller than it believes.
- Drug discovery and development often fail to produce successful product candidates.
- Generic versions of its products, or of competing products, could hurt its business.
- Difficulty managing growth and the risks of buying or in-licensing other drugs or companies.
- Changes in US healthcare laws and policies, and strict regulation of the drug industry.
Income statement
From fiscal 2024 to 2025, earnings per share grew 1,867.7% a year and net income 1,997.1% a year, as new shares raised the share count by 6% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 125 | 58 | 57 | 77 | 155 |
| Debt incl. finance leases | 20 | 40 | 60 | 60 | 52 |
| Net debt (negative means net cash) | −105 | −18 | 3 | −17 | −102 |
| Net debt to EBITDA | — | — | — | −0.7x | −0.8x |
| Debt to equity | 0.7x | — | — | — | 0.1x |
| Interest coverage | −2.6x | −15.0x | −3.0x | 3.1x | 17.1x |
| Current ratio | 2.4x | 1.8x | 1.9x | 2.1x | 2.4x |
| Quick ratio | 2.3x | 1.6x | 1.8x | 2.0x | 2.3x |
Cash flow
Projections
Project Rigel Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Rigel Pharmaceuticals says to expect
- Full year 2026: total revenues
Updated 2026 Outlook: Total revenues of approximately $290 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $260 million and contract revenues from collaborations of approximately $35 million
- Full year 2026: net income
The company also continues to anticipate it will report positive net income for the full year 2026, while funding existing and new clinical development programs.
Insider trades
No officer, director or 10% owner of Rigel Pharmaceuticals reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 7 of 9 | 7 of 9 |
| Rule of 40 | — | — | — |
| Altman Z'' | −37.95 | −23.75 | 0.31 |
| Accruals ratio | −15.4% | −9.9% | 86.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 7 of 9 | 7 of 9 |
Compare
Put Rigel Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | |
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | Compare |
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | Compare |
| Evolus | FY25 | 11.6% | −11.0% | −15.4% | −47.2% | — | 2 | Compare |
| Aurinia Pharmaceuticals | FY25 | 20.4% | 37.1% | 47.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 20 | 4 | 44 | 59 | 109 | 149 | 120 | 117 | 179 | 294 |
| Revenue growth | — | −78.0% | 892.6% | 33.2% | 83.2% | 37.4% | −19.4% | −2.8% | 53.4% | 64.2% |
| Gross profit | — | — | 44 | 58 | 108 | 148 | 118 | 110 | 161 | 275 |
| Research and development | 63 | 46 | 47 | 53 | 60 | 65 | 60 | 24 | 23 | 33 |
| Operating income | −70 | −80 | −73 | −69 | −29 | −12 | −56 | −20 | 24 | 126 |
| Net income | −69 | −78 | −70 | −67 | −30 | −18 | −59 | −25 | 18 | 367 |
| Diluted EPS (US$) | −7.30 | −6.20 | −4.40 | −4.00 | −1.80 | −1.10 | −3.44 | −1.44 | 0.99 | 19.48 |
| Diluted shares (millions) | 9 | 13 | 16 | 17 | 17 | 17 | 17 | 17 | 18 | 19 |
| Cash flow | ||||||||||
| Cash from operations | −76 | −78 | −59 | −42 | −52 | 6 | −74 | −6 | 32 | 76 |
| Capital expenditure | 1 | 0 | 1 | 2 | 1 | 1 | 0 | — | — | — |
| Free cash flow | −77 | −78 | −60 | −43 | −53 | 5 | −74 | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 6 | 8 | 9 | 7 | 10 | 12 | 9 | 12 | 13 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 75 | 116 | 128 | 98 | 57 | 125 | 58 | 57 | 77 | 155 |
| Debt incl. finance leases | — | — | — | 10 | 20 | 20 | 40 | 60 | 60 | 52 |
| Total assets | 78 | 119 | 139 | 148 | 110 | 167 | 134 | 117 | 164 | 514 |
| Total liabilities | 23 | 18 | 29 | 94 | 76 | 137 | 148 | 146 | 161 | 122 |
| Shareholders' equity | 55 | 101 | 110 | 54 | 34 | 30 | −14 | −29 | 3 | 392 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 99.4% | 98.5% | 99.2% | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Operating margin | −342.1% | −1,775.6% | −163.3% | −116.5% | −26.7% | −8.4% | −46.2% | −17.5% | 13.5% | 42.6% |
| Net margin | −339.6% | −1,739.3% | −158.3% | −112.8% | −27.4% | −12.0% | −48.7% | −21.5% | 9.8% | 124.7% |
| Free cash flow margin | −376.3% | −1,733.3% | −134.7% | −72.5% | −49.2% | 3.5% | −61.7% | — | — | — |
| Rule of 40 (growth + FCF margin) | — | −1,811.3% | 758.0% | −39.3% | 34.0% | 40.9% | −81.1% | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | 91.3% |
| Return on equity | −94.5% | −100.2% | −67.0% | −81.7% | −67.7% | −55.6% | −699.0% | — | — | 185.9% |
| Return on assets | −66.0% | −79.1% | −54.6% | −46.7% | −23.1% | −12.9% | −38.8% | −19.9% | 12.4% | 108.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | −0.7x | −0.8x |